Biotech Clinical Development

Cisema provides tailored clinical development and regulatory services for companies advancing next-generation therapies including Cell and Gene Therapies, CAR-T, monoclonal antibodies, peptides, and RNA-based platforms. With over 20 years of experience across China and the Asia Pacific region, we support biotech innovators through clinical strategy, regulatory planning, and post-market surveillance.

Our bilingual teams across Asia align development plans with regional regulatory frameworks to help you manage risk, secure approvals, and ensure long-term compliance. Whether you are an early-stage biotech or scaling for commercialization, Cisema supports your journey with clarity, precision and cross-border insights.

Biotech clinical development
Expert guidance for the biotech industry

Biotech Clinical Development Services

Strategic Clinical Development Planning

We design development strategies that are tailored to the scientific and regulatory demands of advanced biotech therapies, while aligning with the timelines and milestones critical to fundraising, licensing, and market entry across APAC.

Indication definition and competitive landscape assessment
Preclinical-to-clinical transition strategy for novel modalities
Biomarker integration for patient targeting and pharmacodynamic endpoints
Risk-based planning and early regulatory interaction strategy
Statistical considerations including power analysis to support protocol planning
Pediatric study requirements and mitigation planning.

Regulatory GAP Analysis & Fast-Track Access

Innovative biotech products face evolving and market-specific regulatory expectations. Cisema provides strategic insight to ensure your documentation meets APAC authority standards and supports global expansion.

Review of existing clinical data and technical documentation
Gap identification against regulatory requirements in China and APAC
Recommendations for bridging data, additional studies, or real-world evidence inclusion
Support for Breakthrough Therapy Designation, Priority Review, and Conditional Approval pathways
Early engagement planning for authority interactions and submission readiness.

Submission Preparation & Authority Engagement

Cisema serves as your in-region regulatory representative to coordinate submissions and facilitate interactions with health authorities across APAC.

Submission-ready documentation including IND/CTAs
Preparation of Common Technical Document (CTD) modules
Coordination of health authority and ethics committee Q&A
Regulatory communications
Justification reports, risk management files, and safety narratives.

Post-Market Clinical Support & Real-World Data

We support post-approval evidence generation to maintain compliance and demonstrate long-term product value.

Real world evidence (RWE) study planning and design
Post-market surveillance strategy under China’s MAH system and APAC requirements
PMS documentation, PSUR generation, and signal detection guidance
Support for label extension and stakeholder engagement strategies.

Expertise in Advanced Biotech Modalities

Our services support the clinical development of cutting-edge therapies:

Cell and Gene Therapy, including regenerative medicine and genome editing
CAR-T and cell-based immunotherapies
Antibodies and ADCs, including monoclonal antibodies and fusion proteins
Peptides and proteins, for targeted and sustained therapeutic effects
Biotech platforms involving RNA, microbiome, and companion diagnostics.

Request a Proposal from Our Biotech Team

Let Cisema help turn your plans into reality.

Request Proposal

Why Work with Cisema?

Local expertise with global reach

Our bilingual teams bridge international quality standards with local regulations

Proven track record

Over 20 years supporting market approvals and compliance in China and Asia Pacific

End-to-end solutions

From system setup to post-market surveillance, we ensure quality management and regulatory compliance throughout the product lifecycle

Industry breadth

Cross-sector expertise in life sciences, food, veterinary, consumer and industrial goods

Role of a China Agent

Explore Related Services

Health Economics & Market Access

Accelerate access across China and Asia Pacific with confidence. Our market access consulting experts help life sciences companies optimize patient access, navigate pricing and reimbursement challenges, and enable commercial success through real world evidence, health economics, and tailored access strategies.

Learn more

Regulatory Affairs

Navigate regulatory complexity across China and Asia Pacific with confidence. Our regulatory affairs consulting experts support biotech companies with strategic planning, compliant submissions, and local representation to accelerate approvals and ensure market readiness.

Learn more

Pharmacovigilance

Ensure drug safety and regulatory compliance across China and Asia Pacific with confidence. Our pharmacovigilance consulting experts support life sciences companies in managing risks, meeting evolving safety requirements, and maintaining market authorization through end-to-end PV solutions tailored to local regulations.

Learn more

Quality Management & Compliance

Ensure regulatory excellence across China and Asia Pacific with confidence. Our quality management and compliance experts help life sciences companies strengthen GxP systems, streamline audits, and maintain inspection readiness to safeguard market access and operational performance.

Learn more

Latest Insights from Cisema

View More

China NMPA Medical Device Registration Timeline Calculator

Use our interactive calculator to estimate your China NMPA medical device registration timeline, key milestones, and approval window.

November 17, 2026
China NMPA Medical Device Registration Timeline Calculator

Timeline Generator: China NMPA Cosmetics Registration & Filing

Answer a few quick questions and get an estimated timeline for registering/filing your cosmetics in China.

November 17, 2026
Timeline Generator: China NMPA Cosmetics Registration & Filing

Do You Need a China Medical Device Clinical Trial? [Quick Check]

Answer a few quick questions and get a preliminary assessment of whether your medical device requires a China clinical trial for NMPA registration.

November 17, 2026
Do You Need a China Medical Device Clinical Trial? [Quick Check]

Timeline Generator: China NMPA New Cosmetics Ingredients Registration & Filing Timeline Generator

How long will it take to get your new cosmetic ingredient approved in China? Use our interactive calculator to estimate your registration or filing timeline and key milestones.

November 17, 2026
Timeline Generator: China NMPA New Cosmetics Ingredients Registration & Filing Timeline Generator

How the Indonesia Halal Certification Process Works (SIHALAL): A Guide to the SHLN & Regular Certification Pathways

Learn how the BPJPH process works for foreign certificates (SHLN) and regular SIHALAL applications.

November 3, 2026
How the Indonesia Halal Certification Process Works (SIHALAL): A Guide to the SHLN & Regular Certification Pathways

5-Step Guide to the GBA Connect Scheme for Medical Manufacturers

Discover how overseas medical companies can access China early via the GBA Connect Pathway, with a 5-step process and hospital coordination tips.

November 2, 2026
5-Step Guide to the GBA Connect Scheme for Medical Manufacturers
Previous
Previous

Contact Our Biotech Clinical Development Consultants

Let’s discuss how we can support your cell and gene therapy, CAR-T, antibody, or peptide product.

Talk to an Expert